Guest post: Pfizer’s placebo promises (why AstraZeneca may have been right to reject the ‘final’ takeover bid from Pfizer)

Guest post: Pfizer’s placebo promises (why AstraZeneca may have been right to reject the ‘final’ takeover bid from Pfizer)

In front of the Commons Business committee last week, Ian Read, chairman and chief executive of Pfizer, made two points in relation to Pfizer’s commitments, assuming it were to succeed in acquiring the Anglo-Swedish drug manufacturer AstraZeneca.It’s pledged, you may remember, over a minimum period of five years, to: